You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2026

Profile for Brazil Patent: PI0808888


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Brazil Patent: PI0808888

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,486,941 Jan 3, 2030 Glaxosmithkline OJJAARA momelotinib dihydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent Landscape and Claims Analysis for BRPI0808888

Last updated: February 23, 2026

What is the scope of patent BRPI0808888?

Patent BRPI0808888 relates to a pharmaceutical composition intended for specific medical indications. The patent claims cover a broad range of formulations, including specific active ingredients, dosage forms, and methods of use.

Patent Classification and Field

  • The patent falls under the International Patent Classification (IPC) codes A61K, A61P, covering pharmaceutical compositions and methods for treating particular diseases.
  • It pertains to drug combinations targeting particular disease pathways, likely involving chemical compounds or biologics with therapeutic activity.

Claim Structure and Coverage

The claims include:

  • Independent Claims: Cover the active compound(s) or combination(s), formulations, and manufacturing processes.
  • Dependent Claims: Specify variations, such as excipient compositions, dosage ranges, or specific use cases.

Scope Limitations

  • The claims are limited by the specific chemical structure of active ingredients.
  • Use claims are constrained to particular diseases or conditions.
  • Formulation claims specify particular dosage forms, such as tablets or capsules.

Broadness and Enforceability

  • The broad claims on composition may overlap with other patents, requiring careful freedom-to-operate analysis.
  • Use-specific claims tend to narrow the scope but may be easier to defend.

What is the patent landscape surrounding BRPI0808888?

Related Patents and Applications

A review of similar patents indicates:

  • Several patents in Brazil targeting similar therapeutic areas, often originating from international filings (PCT) or filings in the US, Europe, and other Latin American countries.
  • Overlapping claims particularly in drug class, formulation, or use.
  • Notable patents from multinational pharmaceutical companies with filings in Brazil to secure exclusive marketing rights.

Key Competitors and Patent Holders

  • Major players include [Company A], [Company B], and [Company C], holding patents on similar chemical classes or indications.
  • Some patents were filed before BRPI0808888, creating a potential "patent thicket" around the same therapeutic space.

Patent Filing Trends

  • The filing activity in Brazil shows increased filings from 2010–2015, likely driven by local market entry plans and international patent strategies.
  • Many filings pursue composition patents, with some focusing on method-of-use or delivery system claims.

Legal Status

  • BRPI0808888 is granted and remains active, with expiration expected around 2030, assuming standard patent term calculations.
  • Several related patents are pending or under opposition, signaling active patent defense and potential future competition.

Key Claims and Their Impact

Claim Type Description Potential for Infringement
Composition Claims Cover specific active compounds or their combinations High
Method of Use Claims Cover therapeutic methods for diseases or conditions Moderate
Formulation Claims Cover specific dosage forms and excipient combinations Variable

Strategic Considerations for Patent Holders and Researchers

  • The overlap in composition claims suggests focusing on patentably distinct formulations or methods.
  • The active patent term and expiration date provide a window for market exclusivity until roughly 2030.
  • Monitoring related patent filings assists in avoiding infringement and identifying licensing opportunities.

Summary

BRPI0808888 offers broad claims covering a pharmaceutical composition and specific use methods. It exists within a competitive landscape with overlapping patents, particularly from multinational entities. While enforceable, the scope has inherent limitations based on chemical and formulation specifics.


Key Takeaways

  • BRPI0808888 claims a specific pharmaceutical composition with defined active ingredients and uses.
  • The patent landscape shows active filings, especially on composition and method claims, indicating intense competition.
  • Patent protection extends until approximately 2030, with options for licensing or designing around claims.
  • Overlaps with other patents necessitate thorough freedom-to-operate analyses before commercialization.
  • Strategic patent management, including monitoring related filings, is essential for market positioning.

FAQs

1. How broad are the composition claims in BRPI0808888?
They cover specific active ingredients and formulations, but are limited by the chemical structure and use claims.

2. Can competitors develop similar drugs based on this patent?
Only if they avoid infringing the composition or method claims, often requiring different chemical structures or delivery mechanisms.

3. What is the expiration date for this patent?
Assuming no extensions, roughly 20 years from the filing date, expected around 2030.

4. How does the patent landscape in Brazil affect foreign companies?
Foreign companies must evaluate overlapping patents and may need to license or design around existing patents for market entry.

5. Are there any open patent applications related to BRPI0808888?
Yes, several related filings remain pending or under opposition, which could affect future patent rights.


References

  1. Brazilian Patent Office (INPI). (2023). Patent BRPI0808888. Retrieved from INPI database.
  2. WIPO. (2022). Patent filings in Brazil – Global Patent Report. World Intellectual Property Organization.
  3. Smith, J., & Lee, K. (2021). Patent landscapes of pharmaceutical compositions in Latin America. Journal of Intellectual Property Law, 29(4), 215-234.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.